Overview
Spela Mirosevic practices practicing medicine in Ljubljana, Slovenia.
Their clinical expertise encompasses COVID-19, Anal Cancer, Spasticity, and Breast Cancer.
They are actively involved in clinical research, co-authoring 29 peer reviewed articles and participating in 1 clinical trial.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
1 Clinical Trials
Frequently Asked Questions about Spela Mirosevic
Is Spela Mirosevic a top-rated expert for COVID-19?
MediFind is an objective health platform that identifies experts based on real-world data. Spela Mirosevic is classified as an Experienced expert for COVID-19, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Spela Mirosevic participate in research or clinical trials?
Yes. Spela Mirosevic has published 29 articles and abstracts on conditions like COVID-19. You can view a list of Spela Mirosevic's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Anal CancerMirosevic isExperienced. Learn about Anal Cancer.
- Breast CancerMirosevic isExperienced. Learn about Breast Cancer.
- COVID-19Mirosevic isExperienced. Learn about COVID-19.
- SpasticityMirosevic isExperienced. Learn about Spasticity.